Market Overview

Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting

Share:

Company will present safety and tolerability data from Phase 1
clinical trial of CCR2 antagonist CNTX-6970 and 6-month efficacy and
safety data from Phase 2b clinical trial of CNTX-4975 for treatment of
moderate to severe osteoarthritis knee pain

Centrexion
Therapeutics Corporation
, a company focused on developing
non-opioid, non-steroidal therapeutics for the treatment of chronic
pain, today announced it will present Phase 1 safety and tolerability
data of single ascending doses of CNTX-6970 in healthy volunteers and
Phase 2b efficacy and safety data of CNTX-4975 for the treatment of
moderate to severe osteoarthritis knee pain at the 34th
Annual American Academy of Pain Medicine (AAPM) Meeting taking place
April 25 - 29, 2018 at the Vancouver Convention Center in Vancouver,
Canada.

Full abstracts are available online at http://www.painmed.org/2018scientific-abstracts/.
Details of the poster presentations are listed below.

Abstract Title: Phase 1 Study of the Safety and Tolerability of
Single Ascending Doses of the Novel Oral CCR2 Antagonist CNTX-6970 in
Healthy Volunteers
Session Title: Basic Science
Poster
Number
: 111
Presentation Time: Thursday, April 26,
6:00-7:30 p.m. PDT
Location: AAPM Resource Center in the
Vancouver Convention Center

Title: Efficacy and Safety of Intra-Articular CNTX-4975 (Highly
Purified, Synthetic Trans-Capsaicin) in Subjects with Moderate to Severe
Knee Pain Associated with Osteoarthritis: 24-Week Results of a
Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study
Session
Title:
Basic Science
Poster Number: 112
Presentation
Time:
Thursday, April 26, 6-7:30 p.m. PDT
Location: AAPM
Resource Center in the Vancouver Convention Center

About Osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis, affecting
approximately 14 million people in the United States.1 OA
occurs when the protective cartilage on the ends of the bones wears down
over time, and the bone around the joints harden and form edges. These
changes cause pain, swelling and problems moving the joint. OA also
causes an inflammatory process to occur in the affected joint, further
damaging the cartilage. Although OA can damage the majority of joints in
the body, it most commonly affects joints in the knees, hips, hands and
spine. OA can cause pain severe enough that patients experience
difficulty walking, climbing stairs or even rising from a chair. Despite
currently available therapies, many patients opt for total joint
replacement to manage the painful condition.

About CNTX-6970

CNTX-6970 is a novel, potent and selective CCR2 (C-C chemokine receptor
type 2) antagonist with a unique analgesic profile. Recent studies have
shown a close link between chronic pain and the immune system. CNTX-6970
capitalizes on this connection by taking a novel "neuro-immune"
approach. The compound has a dual effect: stopping immune cells from
releasing the potent cytokine MCP-1 (monocyte chemoattractant protein 1)
and stopping MCP-1 from stimulating pain fibers to send pain signals.
CNTX-6970 is predicted to be well suited to treat chronic painful
inflammatory conditions, and a Phase 1 study showed the treatment was
well tolerated with demonstrated pharmacologic and pharmacodynamic
activity.

About CNTX-4975

CNTX-4975 is based on Centrexion's proprietary STRATI™ technology
(Synthetic TRans cApsaicin ulTra-pure Injection), a highly potent,
ultra-pure, synthetic form of trans-capsaicin. CNTX-4975 is designed to
be injected directly into the site of pain to provide rapid onset, large
reduction and long duration of relief from moderate to severe joint pain
without affecting touch sensibility or position sense. CNTX-4975 works
by targeting the capsaicin receptor (TRPV1) to selectively and rapidly
inactivate the local pain fibers transmitting signals to the brain. With
a short half-life, CNTX-4975 is cleared from the body within 24 hours.
This approach is designed to provide pain relief that can last for
months until the ends of the local pain fibers regenerate, while
maintaining normal sensation, such as touch, pressure and position, and
without the risks of toxicities of NSAIDs and injected corticosteroids,
or the side effects, including abuse and addiction, associated with
opioid treatments. In January 2018, CNTX-4975 was granted Fast Track
designation by the U.S. Food and Drug Administration for the treatment
of pain associated with knee osteoarthritis.

About Centrexion Therapeutics

Centrexion Therapeutics Corp. is focused on advancing the treatment of
chronic moderate to severe pain with one of the largest, exclusively
pain-focused pipelines of non-opioid, non-addictive therapies in active
development. Centrexion Therapeutics recognizes the needs of over a
quarter of a billion people living with chronic pain worldwide, and aims
to develop new, safer and more effective therapies that overcome the
limitations and challenges associated with current pain treatments.
Founded by world-renowned leaders in drug development and well-funded by
key investors, Centrexion Therapeutics is building a pain treatment
powerhouse to address the substantial and growing global chronic pain
epidemic. For more information about Centrexion Therapeutics, visit http://www.centrexion.com.

1. Deshpande, B., et al. Number of Persons With Symptomatic Knee
Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex, and
Obesity. Arthritis Care & Research. Published online November 3, 2016

View Comments and Join the Discussion!